![]() ![]() Roswell Park’s NET experts will determine which treatment options - and in which order - are best for you and your cancer. Studies have shown that outcomes for patients with NETs are better when cancer care is coordinated and optimally sequenced. Roswell Park’s multidisciplinary NET team involves several NET oncologists, including thoracic and gastrointestinal surgeons, medical and radiation oncologists plus interventional radiologists, therapeutic endoscopists and experts in nuclear medicine, gastroenterology and endocrinology. NETSPOT, after radiolabeling with Ga 68, is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adults and pediatric patients. Your treatment will likely include more than one type of therapy and the expertise from more than one type of cancer specialist. In addition, the location is important, as NETs in the lungs are often treated differently than NETs in the pancreas. As such, it enables your doctors to develop a precise treatment plan personalized to your particular needs.Treatment for neuroendocrine tumors will depend on your tumor’s type, stage, grade and whether it has spread to lymph nodes or distant areas of your body. Theragnostic care is precision medicine that helps to show the biology behind each type of cancer and how it responds to certain treatments. Combining the diagnostic component with therapy is known as using “paired radiopharmaceuticals.” Your nuclear medicine specialist has special training and will discuss with you the risks and benefits of treatment.Īdditionally, the diagnostic technique may be used again after the targeted therapy is delivered to see how you and your body respond to treatment. A new radioisotope therapy drug called lutetium Lu 177 dotatate, commercially knowns as LUTATHERA, has just been approved by the FDA. These therapies are referred to as “radiopharmaceuticals” because they contain limited amounts of radioactive materials. At Comprehensive and throughout Nevada, the patient-base for neuroendocrine tumors is requesting NETSPOT more and more. Their size makes them difficult to detect early. They can occur anywhere in the body, from the intestines to the lungs to the stomach and pancreas. Phase 2: The doctor uses this same molecular probe to deliver targeted therapies to treat the cancer while preserving healthy tissue around it. NetSpot Neuroendocrine Tumor in Santa Fe Neuroendocrine tumors tend to be quite small. (The probe is sometimes called a “molecular probe” because it looks for a specific kind of molecule). 2 MBq/kg of body weight (0.054 mCi/kg) up to 200 MBq (5.4 mCi) administered as an IV bolus injection. Phase 1: To locate cancer, a doctor specially trained in theragnostic care uses leading-edge molecular probes and diagnostic imaging equipment to precisely locate and define areas of disease. Radioactive diagnostic agent after radiolabeling with Ga 68 indicated for use with positron-emission tomography (PET) for localization of somatostatin receptor-positive neuroendocrine tumors (NETs) in adults and children. The theragnostic care process has two phases: A combination of “therapy” and “diagnostics,” this innovative approach can help treat patients with a range of conditions, including thyroid cancer, prostate cancer that has spread to bone, hyperthyroidism, and neuroendocrine tumors (NET). At Stanford Health Care, the Nuclear Medicine and Molecular Imaging team is helping to lead the development and growing use of theragnostic care. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |